Cardioprotection: Where to from here?
- First Online:
- Cite this article as:
- Kloner, R.A., Hale, S.L., Dai, W. et al. Cardiovasc Drugs Ther (2017) 31: 53. doi:10.1007/s10557-016-6691-0
- 350 Downloads
The size of the myocardial infarction remains an important therapeutic target, because heart attack size correlates with mortality and heart failure. In this era, myocardial infarct size is reduced primarily by timely reperfusion of the infarct related coronary artery. Whereas numerous pre-clinical studies have shown that certain pharmacologic agents and therapeutic maneuvers reduce myocardial infarction size greater than reperfusion alone, very few of these therapies have translated to successful clinical trials or standard clinical use. In this review we discuss both the recent successes as well as recent disappointments, and describe some of the newer potential therapies from the preclinical literature that have not yet been tested in clinical trials.